Company profile: Lexogen
1.1 - Company Overview
Company description
- Provider of next-generation sequencing and transcriptomics solutions, offering whole transcriptome sequencing, small RNA sequencing, and gene expression analysis services, plus SIRVs (Spike-in RNA Variant Control Mixes) for validation and Mix² RNA-Seq data analysis software.
Products and services
- Gene Expression Analysis Services: RNA-Seq-based services that analyze gene expression levels using various RNA sequencing techniques, supplying transcriptomics-focused assessment of expression patterns
- Whole Transcriptome Sequencing: NGS-based service that sequences the entire transcriptome to deliver comprehensive RNA expression data for broad transcriptomics profiling
- SIRVs (Spike-in RNA Variant Control Mixes): spike-in control RNA mixes that validate and benchmark RNA sequencing experiments, enabling performance assessment in transcriptomics workflows
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lexogen
Synlab
HQ: Germany
Website
- Description: Provider of laboratory diagnostics for human and veterinary medicine and environmental analysis services. Delivers wide-ranging laboratory testing, specialty and genetic testing (including preimplantation), supported by 2,000+ medical experts across 30+ countries and 2,000+ blood collection points. Also focuses on medical supplies trade, clinical trials, and consulting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlab company profile →
4basebio
HQ: Germany
Website
- Description: Provider of DNA manufacturing technologies and products for the gene therapy market, including double-stranded DNA formats: hpDNA (hairpinned ends for viral and non-viral vectors), osDNA (with nucleotide modifications for degradation resistance and tunable immunostimulation for DNA vaccines), opDNA and oeDNA for mRNA production and genome editing, the Hermes non-viral delivery platform, and DNA template manufacturing for AAV/Lentivirus with small-scale AAV production and purification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4basebio company profile →
Patch Biosciences
HQ: United States
Website
- Description: Provider of machine-designed DNA and an AI platform for sequence design to engineer more effective and durable gene therapies, leveraging large-scale DNA synthesis and machine learning. Offers synthetic promoter and untranslated region engineering, validated muscle promoters, and robust RNA UTRs for genetic and RNA-based medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Patch Biosciences company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
Adverum Biotechnologies
HQ: United States
Website
- Description: Provider of gene therapy, developing medicines with therapeutic benefits. Offerings include Ixo-vec, a gene therapy product candidate for wet age-related macular degeneration designed for single administration, and the OPTIC clinical program investigating the safety, efficacy, and long-term outcomes of Ixo-vec in wet AMD patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adverum Biotechnologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lexogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lexogen
2.2 - Growth funds investing in similar companies to Lexogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lexogen
4.2 - Public trading comparable groups for Lexogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →